Online GLP-1 Prescriptions Often Lack Clinical Oversight

Written by The Life Science Feed Editorial Team · Published 15 July 2026 · Edited by Mara Voss

> The surge in demand for GLP-1 receptor agonists for weight management has opened a new frontier in telemedicine, offering convenience but often at the expense of comprehensive clinical evaluation. This expedited access to powerful metabolic agents presents a dilemma for clinicians balancing patient desire with the imperative for safe, evidence-based care.1

KEY TAKEAWAYS

- The Pivot: The rapid expansion of online prescribing for GLP-1 agonists has outpaced the establishment of consistent clinical oversight standards.
- The Data: Many online platforms do not mandate baseline laboratory testing, detailed medical history, or ongoing monitoring for patients receiving GLP-1 therapies.
- The Action: Clinicians should counsel patients on the risks of unsupervised GLP-1 use and advocate for comprehensive pre-prescription evaluation and ongoing monitoring, regardless of the prescribing channel.

Obesity and its related cardiometabolic comorbidities represent a significant public health burden across Europe, driving demand for effective pharmacological interventions. GLP-1 receptor agonists, initially developed for type 2 diabetes, have demonstrated substantial efficacy in weight reduction, leading to their approval for chronic weight management in non-diabetic individuals. This efficacy, combined with direct-to-consumer marketing, has fueled an unprecedented demand, pushing many patients towards online platforms for prescription access.

These online services promise speed and convenience, often advertising same-day consultations and rapid medication delivery. But the very efficiency that attracts patients can bypass the rigorous clinical assessments typically required before initiating potent metabolic therapies. A thorough medical history, including a detailed review of comorbidities, current medications, and family history of endocrine neoplasia, is fundamental to safe prescribing. Without this, contraindications or potential drug interactions may be missed.

The Clinical Gaps in Online Prescribing

The standard of care for initiating GLP-1 agonists involves a comprehensive patient evaluation. This includes assessing body mass index (BMI) or weight-related comorbidities, screening for contraindications such as a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and evaluating for a history of pancreatitis or severe gastrointestinal disease. Many online platforms, however, rely on self-reported patient data, which can be incomplete or inaccurate, and often do not mandate baseline laboratory tests. These tests, including renal function, liver enzymes, and sometimes amylase/lipase, are crucial for establishing a safety

baseline and monitoring for adverse effects.

Consider the case of a patient with undiagnosed gastroparesis. GLP-1 agonists slow gastric emptying, which can exacerbate symptoms in such individuals, leading to severe nausea, vomiting, and dehydration. Without a detailed medical history and a clinician actively probing for gastrointestinal symptoms, this risk may go unrecognised. Similarly, patients with a personal history of pancreatitis, even mild, are generally advised against GLP-1 initiation due to the potential for recurrence, a risk that might be overlooked in a rapid online consultation.

Beyond initial screening, ongoing clinical oversight is critical. Patients starting GLP-1 agonists require education on administration, potential side effects, and lifestyle modifications that complement the drug's action. They also need regular follow-up to monitor weight loss progress, assess tolerability, and manage adverse events. Common side effects like nausea, vomiting, diarrhoea, and constipation can be significant, sometimes leading to discontinuation. Without a dedicated clinician providing guidance and adjusting dosage, patients may struggle with these issues or stop treatment prematurely, negating potential benefits.

The rapid titration schedules often employed in clinical trials are designed for closely monitored environments. In an unsupervised online setting, patients may escalate doses too quickly, increasing the likelihood and severity of adverse events. Furthermore, the long-term management of obesity with GLP-1 agonists often involves dose adjustments, switching therapies, or addressing weight plateaus. These decisions require a nuanced understanding of the patient's response and overall health, which is difficult to achieve through asynchronous messaging or brief virtual check-ins.

Another significant concern is the potential for off-label prescribing or the use of compounded versions of GLP-1 agonists. While some online platforms operate within regulatory frameworks, others may offer compounded products that lack the same rigorous quality control and efficacy data as FDA or EMA-approved medications. The active pharmaceutical ingredients in compounded drugs may vary in purity and potency, posing unpredictable risks to patients. Clinicians should be aware that patients seeking online prescriptions may inadvertently receive these unapproved formulations, believing them to be identical to the branded products.

The financial aspect also plays a role. Many patients turn to online services because their insurance does not cover GLP-1 agonists for weight loss, or the out-of-pocket costs are prohibitive. Online platforms may offer more affordable, but less clinically robust, pathways to access. This creates a two-tiered system where patients with greater financial resources or comprehensive insurance coverage receive care under established clinical guidelines, while others may opt for less supervised, potentially riskier alternatives.

The lack of integrated care is an obvious caveat. Traditional medical practice encourages communication between primary care physicians and specialists, ensuring a holistic view of patient health. Online GLP-1 prescribers often operate in isolation, without direct access to a patient's full medical record or the ability to easily communicate with their existing healthcare team. This fragmentation of care can lead to missed diagnoses, conflicting treatment plans, and a general lack of accountability for long-term patient outcomes. A patient's primary care physician may be entirely unaware that their patient is on a powerful GLP-1 agonist, potentially missing opportunities to monitor for side effects or adjust other medications.

The long-term implications of widespread, minimally supervised GLP-1 use are not yet fully understood. While the drugs are generally safe and effective when used appropriately, the sheer volume of prescriptions through less regulated channels could reveal rare but serious adverse events that might otherwise be mitigated by careful patient selection

and monitoring. For example, the risk of acute kidney injury due to dehydration from severe gastrointestinal side effects, while uncommon, is a serious complication that requires prompt clinical intervention. Without a clear line of communication and ongoing monitoring, such events could escalate.

The current regulatory environment for online prescribing services varies significantly by region, creating a patchwork of oversight that can be difficult for patients and clinicians to navigate. Some jurisdictions have stricter requirements for telehealth consultations, mandating synchronous video visits and comprehensive documentation. Others are more permissive, allowing for asynchronous questionnaires and minimal direct patient-provider interaction. This disparity contributes to the inconsistent quality of care observed in the online GLP-1 prescribing landscape.

Ultimately, the convenience of online GLP-1 prescriptions must be weighed against the fundamental principles of medical practice: thorough assessment, informed consent, ongoing monitoring, and integrated care. The responsibility falls to both prescribers, regardless of their platform, and to the broader medical community to educate patients on the importance of comprehensive clinical oversight for these powerful medications.

CLINICAL IMPLICATIONS

The proliferation of online GLP-1 prescriptions without adequate clinical oversight presents a clear and present danger to patient safety. While the convenience is undeniable, the absence of baseline lab work, detailed medical history, and ongoing monitoring means clinicians are flying blind with powerful metabolic agents. GPs and specialists will inevitably see patients presenting with side effects or complications from these online prescriptions, often without full knowledge of the drug, dose, or even the exact formulation. This necessitates a proactive approach: inquire about all medications, including those obtained online, and educate patients on the critical need for comprehensive medical evaluation before starting any new therapy.

The industry, including pharmaceutical manufacturers and regulatory bodies, must address this growing gap. Clearer guidelines for telehealth prescribing of GLP-1 agonists are urgently needed, mandating the same standard of care as in-person consultations. Otherwise, the benefits of these transformative drugs risk being overshadowed by preventable adverse events and fragmented care.

Patients, driven by the desire for weight loss and often facing barriers to traditional care, are vulnerable to services that prioritise speed over safety. It is incumbent upon the medical community to advocate for robust clinical standards across all prescribing channels, ensuring that access to effective treatments does not come at the cost of responsible medical practice.

REFERENCES

1. 1. Gorgojo-Martínez JJ, et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022;12(1). doi:10.3390/jcm12010145
2. 2. Elmaleh-Sachs A, et al. Obesity Management in Adults: A Review. JAMA. 2023;330(20):2000-2015. doi:10.1001/jama.2023.19897

3. 3. Gudzune KA, et al. Medications for Obesity: A Review. JAMA. 2024;332(7):571-584. doi:10.1001/jama.2024.10816

4. 4. Kunutsor SK, et al. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. Drugs. 2026;86(1):11-36. doi:10.1007/s40265-025-02263-0

5. 5. Jalleh RJ, et al. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions. Lancet Gastroenterol Hepatol. 2024;9(10):957-964. doi:10.1016/S2468-1253(24)00188-2

6. 6. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring). 2025;33(8):1475-1503. doi:10.1002/oby.24336